ASSOCIATION EISBM

Their core work

ASSOCIATION EISBM (European Institute for Systems Biology and Medicine) is a French research association specializing in systems medicine, real-world evidence generation, and data-driven clinical research. Their core work involves synthesizing heterogeneous data sources — clinical registries, genomic data, and real-world outcomes — to address evidence gaps and inform treatment guidelines for cancer and other serious diseases. In practice, they contribute methodological expertise to large European consortia: designing research prioritization frameworks, defining data requirements, and applying artificial intelligence to improve patient stratification and treatment decision support. They operate as a specialist scientific partner, bringing systems biology methods into applied oncology research.

What they specialise in

How they've shifted over time

In their earlier work (PIONEER, starting 2018), EISBM focused on the upstream challenges of cancer research: identifying what evidence is missing, mapping genetic profiles and natural history of disease, and establishing frameworks for research prioritization using multidisciplinary data. By their second project (OPTIMA, starting 2021), the emphasis shifted decisively toward the downstream application layer — real-world evidence, clinical guidelines, and artificial intelligence for treatment optimization. The trajectory is clear: from evidence mapping and methodology to AI-driven clinical decision support.

EISBM is moving from methodological and evidence-mapping roles toward applied AI and clinical guideline development, making them a strong candidate for future projects at the intersection of real-world data, oncology, and machine learning.

How they like to work

EISBM exclusively participates as a consortium partner — they have never led an H2020 project as coordinator. They operate within large, multi-country consortia (61 partners across 17 countries across just 2 projects), suggesting they are sought as specialist contributors rather than project managers. This profile indicates an organization that brings a defined methodological niche — systems medicine, evidence synthesis, AI — rather than end-to-end project leadership capacity.

Despite only two projects, EISBM has connected with 61 unique partners across 17 countries — an unusually broad network for an organization of this size, pointing to active participation in large pan-European research consortia. Their reach is genuinely European, spanning clinical, academic, and data-infrastructure partners across the continent.

What sets them apart

EISBM sits at a specific and valuable intersection: systems biology methodology applied to clinical oncology, with particular strength in evidence synthesis and AI-assisted treatment optimization — a combination that is not common among French research associations. For a consortium needing someone to bridge computational data science and clinical research design (especially in cancer), EISBM offers a focused, credible track record without the overhead of a large university research group. Their consistent participation in high-value RIA projects (average €821K per grant) confirms that larger consortia consider them worth funding as specialist nodes.

Highlights from their portfolio

• OPTIMA
  The largest grant EISBM has received (€884,000), running to 2026, placing AI at the center of treatment optimization for solid tumours — their most forward-looking and technically ambitious project to date.
• PIONEER
  A flagship prostate cancer big-data project (2018–2023) that established EISBM's credentials in multi-source clinical data analysis and evidence gap methodology at the European scale.